All lobbying filings
TEVA PHARMACEUTICALS USA, INC.
TEVA PHARMACEUTICALS USA, INC. filed a Q3 report for TEVA PHARMACEUTICALS USA INC on October 17, 2025.
Lobbying for TEVA PHARMACEUTICALS USA INC
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 17, 2025
Expenses
$460,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
New Jersey
Government bodies contacted
9
Lobbying activity
2
Use of Section viii statements in pharmaceutical labeling. Changes to Hatch-Waxmans 180-day exclusivity incentive. Changes to FDA approval process for pharmaceuticals. Implementation of the Inflation Reduction Act. Drug pricing proposals. Oversight and legislation to reform pharmacy benefit managers. Patent reform legislation. Proposals related to drug shortages. Reauthorization of the Pandemic and All Hazards Preparedness Act (PAHPA).
A joint resolution terminating the national emergency declared to impose duties on articles imported from Canada (S.J.Res.37).
Bills named in this filing
1